Valuation: Fate Therapeutics, Inc.

Market Cap 277M 238M 226M 205M 384M 26.44B 386M 2.68B 1.03B 13.45B 1.04B 1.02B 42.51B P/E 2026 *
-2.16x
P/E 2027 * -2.23x
Enterprise Value 277M 238M 226M 205M 384M 26.44B 386M 2.68B 1.03B 13.45B 1.04B 1.02B 42.51B EV / Sales 2026 *
49x
EV / Sales 2027 * 58.1x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day+1.08%
1 week-7.00%
Current month-2.72%
1 month-9.53%
3 months+15.67%
6 months+100.43%
Current year+136.62%
1 week 2.28
Extreme 2.28
2.55
1 month 2.23
Extreme 2.23
2.7
Current year 0.97
Extreme 0.97
3.23
1 year 0.94
Extreme 0.9401
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
72.29
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
4/8/26 Sell

Chief Executive Officer

-43,947 0.0377%
4/8/26 Sell

Compliance Officer

-38,800 0.0333%
12/6/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-7.00%+143.25%-1.48% 277M
+5.04%+3.27%+50.62%+105.43% 66.93B
+1.64%-0.18%+36.02%+76.81% 61.97B
-3.18%+0.42%-12.38%+370.27% 28.26B
+4.55%-0.08%+34.70%+17.28% 24.59B
+2.75%+0.67%+1.47%-12.73% 24.3B
+1.15%-1.17%+18.94%-21.92% 19.41B
-7.03%-9.16%+161.91%+303.00% 16.77B
+3.44%-1.68%-5.00%+541.17% 14.18B
+6.55%+7.93%-1.53%+876.44% 14B
Average +1.60%-4.24%+42.80%+225.43% 27.07B
Weighted average by Cap. +2.12%-2.85%+33.95%+173.61%

Financials

2026 *2027 *
Net sales 5.65M 4.87M 4.61M 4.18M 7.84M 540M 7.88M 54.74M 21.05M 275M 21.22M 20.75M 868M 4.77M 4.11M 3.89M 3.52M 6.61M 455M 6.65M 46.18M 17.76M 232M 17.9M 17.51M 732M
Net income -129M -111M -105M -95.26M -179M -12.31B -180M -1.25B -480M -6.26B -484M -473M -19.79B -146M -126M -119M -108M -203M -13.95B -204M -1.41B -544M -7.1B -548M -536M -22.43B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
15/09/26 USD 2.320 +0.43% 159,763
11/09/26 USD 2.310 -0.86% 742,393
10/09/26 USD 2.330 -4.51% 751,111
09/09/26 USD 2.440 -2.40% 553,575
08/09/26 USD 2.500 +0.81% 1,918,069
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2.310USD
Average target price
5.744USD
Spread / Average Target
+148.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!